ChemoCentryx, Inc.
CCXI · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $32,224 | $64,891 | $35,952 | $42,875 |
| % Growth | -50.3% | 80.5% | -16.1% | – |
| Cost of Goods Sold | $302 | $0 | $0 | $0 |
| Gross Profit | $31,922 | $64,891 | $35,952 | $42,875 |
| % Margin | 99.1% | 100% | 100% | 100% |
| R&D Expenses | $82,990 | $77,882 | $70,276 | $62,736 |
| G&A Expenses | $0 | $42,186 | $24,155 | $20,409 |
| SG&A Expenses | $78,851 | $42,186 | $24,155 | $20,409 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $302 | $0 | -$176 | $0 |
| Operating Expenses | $162,143 | $120,068 | $94,255 | $83,145 |
| Operating Income | -$134,450 | -$55,177 | -$58,303 | -$40,270 |
| % Margin | -417.2% | -85% | -162.2% | -93.9% |
| Other Income/Exp. Net | -$1,836 | -$179 | $2,814 | $2,304 |
| Pre-Tax Income | -$131,755 | -$55,356 | -$55,489 | -$37,966 |
| Tax Expense | -$2,695 | $0 | $0 | $0 |
| Net Income | -$129,060 | -$55,356 | -$55,489 | -$37,966 |
| % Margin | -400.5% | -85.3% | -154.3% | -88.6% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 |
| % Growth | -133.3% | 14.3% | -28.9% | – |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 |
| Weighted Avg Shares Out | 65,688 | 65,688 | 56,898 | 49,814 |
| Weighted Avg Shares Out Dil | 65,688 | 65,688 | 56,898 | 49,814 |
| Supplemental Information | – | – | – | – |
| Interest Income | $859 | $2,464 | $4,963 | $3,528 |
| Interest Expense | -$2,695 | $2,643 | $2,149 | $1,224 |
| Depreciation & Amortization | $3,139 | $797 | $1,642 | $512 |
| EBITDA | -$131,311 | -$51,916 | -$51,698 | -$36,230 |
| % Margin | -407.5% | -80% | -143.8% | -84.5% |